What Beinaglutide is
Beinaglutide is a GLP-1 receptor agonist used in some markets and tracked here as part of the broader incretin-drug landscape.
Beinaglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it matters because it expands the view beyond only the most visible US GLP-1 products.
The useful starting point is to separate the molecule itself from the internet story around it. It matters because it expands the view beyond only the most visible US GLP-1 products.
Why people keep looking it up
It matters because it expands the view beyond only the most visible US GLP-1 products.
Beinaglutide is a GLP-1 receptor agonist used in some markets and tracked here as part of the broader incretin-drug landscape.
Beinaglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucose control, and weight regulation. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Human metabolic evidence exists, with regulatory context that is more mixed than the major US brands.
Human clinical evidence exists, though market and regulatory context vary by country and product.
Mechanistic support follows GLP-1 receptor pharmacology.
Why this page carries the current tier: Human metabolic evidence exists, with regulatory context that is more mixed than the major US brands.
The current seed trail for Beinaglutide is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Market-specific availability and regulatory context should be verified directly rather than assumed from general GLP-1 headlines.
Regulatory status depends on geography and should be checked against current official sources.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Beinaglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Beinaglutide is CID 16209124. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16209124
- Formula
- C149H225N39O46
- Molecular weight
- 3298.6
- InChIKey
- NGJOFQZEYQGZMB-KTKZVXAJSA-N
Matched synonyms include 123475-27-4, beinaglutida, beinaglutidum, RefChem:1077779, 38I1O6L31D, Beinaglutide, Glp-1 (7-36), Glucagon like peptide-i (7-36).
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Beinaglutide returns 3 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Beinaglutide returns 31 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.